</s><s><s><s> during the postlicensure period from 2006 to 2014, a total of 96 reports of death after receiving human papillomavirus quadrivalent ( types 6, 11, 16, and 18 ) vaccine, recombinant ( recombinant ), were submitted to the united states department of health and human services, food and drug administration, and the vaccine safety and efficacy evaluation system ( VAERS ). 
 of the 96 reports, 47 deaths were considered confirmed in that the reports included a certificate of death, autopsy report, or other medical documentation of death. among the 7.6% of total reports classified as serious, headache, nausea, vomiting, and fever were the most frequently reported symptoms for both males and females. </s>